13.02.2014 • News

Reckitt Benckiser Says Pharma Review Ongoing

Reckitt Benckiser has said the strategic review of its pharmaceuticals business is still in progress and it will update investors over the course of 2014.

In October 2013, the company said it was considering all options for the business, which could include selling it, spinning it off, or keeping it.

Regarding acquisitions, CEO Rakesh Kapoor said Reckitt would continue to be active in the consumer health space, but declined to comment specifically on reports that consumer companies have approached U.S. drug maker Merck & Co about its consumer business.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read